Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas
暂无分享,去创建一个
Jessica Zucman-Rossi | Sandrine Imbeaud | Julien Calderaro | Alexis Laurent | Maxime Mallet | S. Imbeaud | J. Zucman‐Rossi | E. Letouzé | J. Calderaro | C. Balabaud | P. Bioulac-Sage | G. Couchy | F. Calvo | J. Nault | J. Blanc | M. Letexier | A. Laurent | Shalini Datta | Fabien Calvo | Jean-Charles Nault | Eric Letouzé | C. Pilati | Jean-Frédéric Blanc | Paulette Bioulac-Sage | Charles Balabaud | Mélanie Letexier | A. Franconi | M. Mallet | B. Verret | Camilla Pilati | Shalini Datta | Andrea Franconi | Gabrielle Couchy | Benjamin Verret | S. Datta | Benjamin Verret
[1] Jessica Zucman-Rossi,et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.
[2] A. Elkahloun,et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. , 2015, The Journal of clinical investigation.
[3] J. Zucman‐Rossi,et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis , 2014, Hepatology.
[4] Hiromi Nakamura,et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes , 2014, Nature Genetics.
[5] Jessica Zucman-Rossi,et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. , 2014, Cancer cell.
[6] Koichiro Tamura,et al. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. , 2013, Molecular biology and evolution.
[7] J. Zucman‐Rossi,et al. Corrigendum: High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions , 2013, Nature Communications.
[8] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..
[9] Na Zhao,et al. Recurrent Targeted Genes of Hepatitis B Virus in the Liver Cancer Genomes Identified by a Next-Generation Sequencing–Based Approach , 2012, PLoS genetics.
[10] K. L. La Perle,et al. Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[11] Keith A. Boroevich,et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators , 2012, Nature Genetics.
[12] Angela M. Liu,et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma , 2012, Nature Genetics.
[13] Pei-Rong Wang,et al. Induction of hepatocellular carcinoma by in vivo gene targeting , 2012, Proceedings of the National Academy of Sciences.
[14] S. Imbeaud,et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma , 2012, Nature Genetics.
[15] J. Bruix,et al. Hepatocellular carcinoma , 2012, The Lancet.
[16] David R. Kelley,et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.
[17] Pratima Chowdary,et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. , 2011, The New England journal of medicine.
[18] A. Rezai,et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial , 2011, The Lancet Neurology.
[19] P. Moore,et al. Why do viruses cause cancer? Highlights of the first century of human tumour virology , 2010, Nature Reviews Cancer.
[20] E. Wang,et al. Analysis and design of RNA sequencing experiments for identifying isoform regulation , 2010, Nature Methods.
[21] M. Buendia,et al. Mechanisms of HBV-related hepatocarcinogenesis. , 2010, Journal of hepatology.
[22] Richard Durbin,et al. Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..
[23] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[24] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[25] Lior Pachter,et al. Sequence Analysis , 2020, Definitions.
[26] James M. Wilson,et al. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. , 2009, The Journal of infectious diseases.
[27] J. Maguire,et al. Solution Hybrid Selection with Ultra-long Oligonucleotides for Massively Parallel Targeted Sequencing , 2009, Nature Biotechnology.
[28] S. Imbeaud,et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours , 2009, Nature.
[29] J. Gutkind,et al. Human tumor-associated viruses and new insights into the molecular mechanisms of cancer , 2008, Oncogene.
[30] Mark J. Smyth,et al. The TRAIL apoptotic pathway in cancer onset, progression and therapy , 2008, Nature Reviews Cancer.
[31] R. H. Smith,et al. Adeno-associated virus integration: virus versus vector , 2008, Gene Therapy.
[32] Daniel G. Miller,et al. AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma , 2007, Science.
[33] R. Owens,et al. Preferential Integration of Adeno-Associated Virus Type 2 into a Polypyrimidine/Polypurine-Rich Region within AAVS1 , 2007, Journal of Virology.
[34] E. Furth,et al. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[35] J. Emerson,et al. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. , 2006, Human gene therapy.
[36] M. Gonçalves. Adeno-associated virus: from defective virus to effective vector , 2005, Virology Journal.
[37] T. Flotte,et al. Adeno-associated virus: a ubiquitous commensal of mammals. , 2005, Human gene therapy.
[38] P. Hinds,et al. Cyclins and cdks in development and cancer: a perspective , 2005, Oncogene.
[39] Cristel G. Thomas,et al. Germline hepatocyte nuclear factor 1α and 1β mutations in renal cell carcinomas , 2005 .
[40] Yoshiki Murakami,et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene , 2003, Oncogene.
[41] R. Haberman,et al. Novel Transcriptional Regulatory Signals in the Adeno-Associated Virus Terminal Repeat A/D Junction Element , 2000, Journal of Virology.
[42] C. Bréchot,et al. Oncogenic activation of a human cyclin A2 targeted to the endoplasmic reticulum upon Hepatitis B virus genome insertion , 1998, Oncogene.
[43] T. Flotte,et al. Expression of the human multidrug resistance and glucocerebrosidase cDNAs from adeno-associated vectors: efficient promoter activity of AAV sequences and in vivo delivery via liposomes. , 1996, Human gene therapy.
[44] M. Nei,et al. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. , 1993, Molecular biology and evolution.
[45] D. Housman,et al. Targeted integration of adeno‐associated virus (AAV) into human chromosome 19. , 1991, The EMBO journal.
[46] C. Bréchot,et al. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma , 1990, Nature.
[47] M. Rocchi,et al. Site-specific integration by adeno-associated virus. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[48] F. Corpet. Multiple sequence alignment with hierarchical clustering. , 1988, Nucleic acids research.
[49] A. Hope. A Simplified Monte Carlo Significance Test Procedure , 1968 .
[50] B. Casto,et al. Adenovirus-Associated Defective Virus Particles , 1965, Science.